Effective pharmacotherapy of alcoholic amnestic disorder with fluvoxamine. Preliminary findings.
Arch Gen Psychiatry
; 46(7): 617-21, 1989 Jul.
Article
en En
| MEDLINE
| ID: mdl-2472126
ABSTRACT
Ten patients with alcoholic chronic organic brain disease were categorized as having alcohol amnestic disorder, or Korsakoff's psychosis (n = 6), dementia associated with alcoholism (n = 3), or compensated alcoholic liver disease (n = 1). All patients had severe deficits in memory for recently acquired information (episodic memory). Patients with alcohol dementia also showed global intellectual decline, including decreased performance on measures of semantic (knowledge) memory and reduction in levels of cerebrospinal fluid somatostatin. In a 4-week double-blind crossover design, the serotonin-uptake blocker fluvoxamine maleate (100 to 200 mg/d) was found to improve episodic memory in only the patients with alcohol amnestic disorder. These improvements in memory were significantly correlated with reductions in levels of cerebrospinal fluid 5-hydroxyindoleacetic acid, suggesting that facilitation of serotonergic neurotransmission may ameliorate the episodic memory failure in patients with alcohol amnestic disorder.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Oximas
/
Antagonistas de la Serotonina
/
Trastorno Amnésico Alcohólico
Tipo de estudio:
Clinical_trials
/
Diagnostic_studies
Límite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Arch Gen Psychiatry
Año:
1989
Tipo del documento:
Article